Juvenile Laryngeal Papillomatosis - Immunisation with the Polyvalent Vaccine Gardasil®

被引:34
作者
Foerster, G. [1 ]
Boltze, C. [2 ]
Seidel, J. [3 ]
Pawlita, M. [4 ]
Mueller, A. [1 ]
机构
[1] SRH Wald Klinikum Gera, Klin HNO Heilkunde Plast Operat, D-07548 Gera, Germany
[2] Univ Rostock, Fak Med, Inst Pathol, SRH Wald Klinikums Gera, D-2500 Rostock 1, Germany
[3] SRH Wald Klinikums Gera, Klin Kinder & Jugendmed, D-07548 Gera, Germany
[4] Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Infekt & Krebs, Heidelberg, Germany
关键词
larynx; papillomavirus; HPV; Gardasil; laryngeal papillomatosis; case report;
D O I
10.1055/s-2008-1077527
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Juvenile laryngeal papillomatosis is a rare condition caused by human papilloma virus (HPV). In cases with rapid recurrences permanent impairments of voice and breathing are almost inevitable due to the frequent need of debulking surgeries. Efforts to lower the recurrence rate comprise the adjuvant use of interferon alpha, local cidofovir, photodynamic therapy or mumps vaccination. In the present case we tried to positively influence the aggressive course of disease in a two year old boy by immunisation with the quadrivalent HPV vaccine Gardasil (R). Chromogenic in-situ hybridisation analysis and polymerase chain reaction (PCR) of lesion tissue showed simultaneous infection with the HPV-Types 6 and 11. After the third immunisation the disease became stable. No further surgery was necessary for the last ten months. The risk profile of this adjuvant treatment is low. We think it worth to initiate a multicentre trial to prove a benefit of this treatment even if no complete virus elimination can be achieved.
引用
收藏
页码:796 / 799
页数:4
相关论文
共 23 条
[1]   Human papillomavirus in larynx [J].
Aaltonen, LM ;
Rihkanen, H ;
Vaheri, A .
LARYNGOSCOPE, 2002, 112 (04) :700-707
[2]  
Alberico S, 1996, Minerva Ginecol, V48, P199
[3]  
Chen Bo-bei, 2003, Zhonghua Er Bi Yan Hou Ke Za Zhi, V38, P417
[4]  
DERKAY CS, 1995, ARCH OTOLARYNGOL, V121, P1386
[5]   Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases [J].
Garland, Suzanne M. ;
Hernandez-Avila, Mauricio ;
Wheeler, Cosette M. ;
Perez, Gonzalo ;
Harper, Diane M. ;
Leodolter, Sepp ;
Tang, Grace W. K. ;
Ferris, Daron G. ;
Steben, Marc ;
Bryan, Janine ;
Taddeo, Frank J. ;
Railkar, Radha ;
Esser, Mark T. ;
Sings, Heather L. ;
Nelson, Micki ;
Boslego, John ;
Sattler, Carlos ;
Barr, Eliav ;
Koutsky, Laura A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (19) :1928-1943
[6]   Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up [J].
Gerein, V ;
Rastorguev, E ;
Gerein, J ;
Jecker, P ;
Pfister, H .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2005, 114 (06) :463-471
[7]   Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience [J].
Gerein, V ;
Rastorguev, E ;
Gerein, J ;
Draf, W ;
Schirren, J .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2005, 132 (03) :392-394
[8]  
Glastetter E, 2007, HAUTARZT, V58, P493, DOI 10.1007/s00105-007-1339-4
[9]   Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia [J].
Hallez, S ;
Simon, P ;
Maudoux, F ;
Doyen, J ;
Noël, JC ;
Beliard, A ;
Capelle, X ;
Buxant, F ;
Fayt, I ;
Lagrost, AC ;
Hubert, P ;
Gerday, C ;
Burny, A ;
Boniver, J ;
Foidart, JM ;
Delvenne, P ;
Jacobs, N .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (07) :642-650
[10]  
HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057